EGFR and metastatic colorectal cancer: This study suggests that a facial skin type with a high number of enlarged pores may be a marker for predicting AfR risk due to anti‐EGFR antibody therapy and better therapeutic effects for RAS wild‐type metastatic colorectal cancer.